Log in

NASDAQ:OPK - Opko Health Stock Price, Forecast & News

$1.57
0.00 (0.00 %)
(As of 02/16/2020 02:16 PM ET)
Add
Today's Range
$1.54
Now: $1.57
$1.59
50-Day Range
$1.44
MA: $1.53
$1.73
52-Week Range
$1.33
Now: $1.57
$2.88
Volume2.00 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:OPK
CUSIP68375N10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees5,690
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.


Opko Health (NASDAQ:OPK) Frequently Asked Questions

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. The biotechnology company had revenue of $228.80 million for the quarter, compared to analysts' expectations of $225.40 million. The business's revenue for the quarter was down 8.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.05) EPS. View Opko Health's Earnings History.

When is Opko Health's next earnings date?

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

What price target have analysts set for OPK?

2 Wall Street analysts have issued 1-year target prices for Opko Health's stock. Their forecasts range from $2.50 to $4.00. On average, they expect Opko Health's share price to reach $3.25 in the next year. This suggests a possible upside of 107.0% from the stock's current price. View Analyst Price Targets for Opko Health.

What is the consensus analysts' recommendation for Opko Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

News articles about OPK stock have been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Opko Health earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Opko Health.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 80,770,000 shares, an increase of 5.5% from the December 31st total of 76,560,000 shares. Based on an average daily volume of 5,380,000 shares, the short-interest ratio is currently 15.0 days. Currently, 20.2% of the company's shares are sold short. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), Novavax (NVAX) and Bausch Health Companies (BHC).

Who are Opko Health's key executives?

Opko Health's management team includes the folowing people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

Who are Opko Health's major shareholders?

Opko Health's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (2.69%), Oracle Investment Management Inc. (0.66%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.45%), Marshall Wace LLP (0.38%), Farallon Capital Management LLC (0.38%) and Charles Schwab Investment Management Inc. (0.37%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Which major investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Bank of Montreal Can, X Square Capital LLC, Connor Clark & Lunn Investment Management Ltd., Rafferty Asset Management LLC, Cito Capital Group LLC, Prudential Financial Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for Opko Health.

Which major investors are buying Opko Health stock?

OPK stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, Farallon Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Jane Street Group LLC and Chicago Equity Partners LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.57.


MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  442 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  871
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel